Binding of d-tubocurarine di (methyl-14C) ether iodide and other amines to cartilage, chondroitin sulfate and human plasma proteins

GD Olsen, EM Chan and WK Riker

The binding of d-tubocurarine di [methyl-14C] ether iodide (d-TCE) and other amines to bovine nasal septum, chondroitin sulfate (CS) and human plasma proteins was examined by equilibrium dialysis. Bovine nasal septum and CS bound d-TCE to a greater extent than they did morphine, d- methadone (d-ME) and l-methadone (l-ME). Cartilage, relative to an equal weight of pure CS, bound slightly more d-TCE, 50% more d-ME and l- ME, and the same amount of morphine. The amount of d-TCE bound to pure CS was similar to that of decamethonium [methyl-14C] dibromide but less than that of two new iodinated bisquaternary compounds: 1,6-bis(N,N- dimethyl-3-iodobenzylamino)hexane dichloride and 1,6-bis[dimethyl-(3- amino-4,6-diiodo-benzyl)amino]hexane dichloride. The binding of d-TCE is greater for pure CS than for impure CS which contains 26% protein, and binding to either preparation was inversely related to sodium ion concentration. In the drug concentration range explored, 30 to 40% of d- TCE is bound to plasma proteins, which is twice that of decamethonium binding but equivalent to the binding of morphine and about one-half the binding of d-ME and l-ME. In this same drug concentration range, each gram of cartilage (dry weight) can bind about 10(-7) mol of d-TCE. This study suggests that the binding of d-TCE to cartilage is an ionic type bonding to the anionic sites of the ester sulfates and glucuronate moieties of CS and that the binding of d-TCE to the protein fraction of cartilage is probably equal to, or less than, its binding to the CS fraction. It is concluded that cartilage may represent a measurable distribution pool for d-tubocurarine.

Volume 195, Issue 2, pp. 242-250, 11/01/1975
Copyright © 1975 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				P. Dulvadestin, A. Gilton, P. Hernigou, and J. Marty The Onset Time of Atracurium Is Prolonged in Patients with Sickle Cell Disease Anesth. Analg., July 1, 2008; 107(1): 113 - 116. [Abstract] [Full Text] [PDF]

				M. Ollier, J.-C. Maurizis, C. Nicolas, J. Bonafous, M. de Latour, A. Veyre, and J.-C. Madelmont Joint Scintigraphy in Rabbits with 99mTc-N-[3-(triethylammonio)propyl]-15ane-N5, a New Radiodiagnostic Agent for Articular Cartilage Imaging J. Nucl. Med., January 1, 2001; 42(1): 141 - 145. [Abstract] [Full Text] [PDF]

				J.-C. Maurizis, M. Rapp, C. Nicolas, M. Ollier, M. Verny, and J.-C. Madelmont Disposition in Rats of N-Pyridinium-propyl-cyclam, N-Triethylammonium-propyl-cyclam, and N-[Triethylammonium]-3-propyl-[15]ane-N5, Potential Cartilage Imaging Agents Drug Metab. Dispos., April 1, 2000; 28(4): 418 - 422. [Abstract] [Full Text]